CommercialPrior AuthLow impact
Islet Transplantation for Chronic Pancreatitis and Donislecel-jujn for Type 1 Diabetes
Blue Cross & Blue Shield of Mississippi·MS · Endocrinology, General Surgery, Gastroenterology·Medical Policy
We identified it
Jun 20, 2026
Summary
Blue Cross Blue Shield of Mississippi updated their islet transplantation policy to specify that allogeneic islet transplantation using FDA-approved donislecel-jujn (Lantidra) is considered investigational for type 1 diabetes treatment. Autologous islet transplantation remains covered as medically necessary when performed with pancreatectomy for chronic pancreatitis, but requires prior authorization through Case Management.
Action Required
Immediately: Billing team must ensure prior authorization is obtained through Case Management for all islet transplantation procedures before scheduling. Update billing system to flag these procedures as investigational when performed for type 1 diabetes with donislecel-jujn. Claims will be denied without proper prior authorization.